The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in ...
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and ...
Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more ...
There is a wide range of possibilities.
How over-the-top social media videos about psychedelics could undermine the field’s efforts to get its drugs approved.
BIO-Europe Spring 2026 brought together more than 3,700 innovators in the life sciences industry all under the same roof.
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
ASX biotechs have enlisted to help the US military to protect soldiers against germ warfare attacks and – the enemy ... Read ...
We explore what allosteric modulators are, their benefits and drawbacks, and which candidates are currently advancing through ...
The rare disease space has always been uniquely difficult for drug development, but recent regulatory developments are ...
FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur. The rare disease space has always been uniquely difficult for drug ...
They could make important breakthroughs in their target markets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results